ESR1 and breast carcinoma: These results validate the use of the PIK3CA mutational status test performed at those centers in the clinical diagnostics of patients with advanced ER+/HER2-breast carcinoma and enable these patients to be selected for an additional treatment option with PI3Kα inhibitors.